Radalbuvir

Radalbuvir
Clinical data
Other names	GS-9669
Legal status
Legal status	US: Investigational New Drug ;
Identifiers
	IUPAC name 5-(3,3-Dimethylbut-1-yn-1-yl)-3-{(1R)-N-[(1s,4s)-4-hydroxy-4-({[(3S)-oxolan-3-yl]oxy}methyl)cyclohexyl]-4-methylcyclohex-3-ene-1-carboxamido}thiophene-2-carboxylic acid;
CAS Number	1314795-11-3;
PubChem CID	53259022;
ChemSpider	31140180;
UNII	273K4V0SPC;
Chemical and physical data
Formula	C30H41NO6S
Molar mass	543.72 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC[C@@H](CC1)C(=O)N([C@H]2CC[C@](CC2)(O)CO[C@@H]3COCC3)c4c(sc(c4)C#CC(C)(C)C)C(=O)O;
	InChI InChI=1S/C30H41NO6S/c1-20-5-7-21(8-6-20)27(32)31(25-17-24(11-13-29(2,3)4)38-26(25)28(33)34)22-9-14-30(35,15-10-22)19-37-23-12-16-36-18-23/h5,17,21-23,35H,6-10,12,14-16,18-19H2,1-4H3,(H,33,34)/t21-,22-,23-,30+/m0/s1; Key:MUICUPWICXUNRS-GDCCIXDYSA-N;

Radalbuvir (INN,[1] also known as GS-9669) is an experimental antiviral drug for the treatment of hepatitis C virus (HCV) infection developed by Gilead Sciences. Radalbuvir acts as an NS5B inhibitor. It is currently in clinical trials.[2] It targets NS5B polymerase.[3]

References

"International Nonproprietary Names for Pharmaceutical Substances" (PDF). WHO Drug Information. 28 (4). 2014.
"Search of: GS-9669 — List Results". ClinicalTrials.gov.
Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR (March 2018). "NS5B polymerase inhibitors in phase II clinical trials for HCV infection". Expert Opinion on Investigational Drugs. 27 (3): 243–250. doi:10.1080/13543784.2018.1420780. PMID 29271672.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "International Nonproprietary Names for Pharmaceutical Substances" (PDF). WHO Drug Information. 28 (4). 2014.

[2] "Search of: GS-9669 — List Results". ClinicalTrials.gov.

[pmid29271672-3] Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR (March 2018). "NS5B polymerase inhibitors in phase II clinical trials for HCV infection". Expert Opinion on Investigational Drugs. 27 (3): 243–250. doi:10.1080/13543784.2018.1420780. PMID 29271672.